Immunophenotyping assessment in a COVID-19 cohort (IMPACC): A prospective longitudinal study

• Type of Material: Article
• Authors: Nadine Rouphael, Emory University; Holden Maecker, Stanford University; Ruth R. Montgomery, Yale University; Joann Diray-Arce, Harvard Medical School; Steven H. Kleinstein, Yale University; Matthew C. Altman, Benaroya Research Institute; Steven Bosinger, Emory University; Walter Eckalbar, University of California San Francisco; Bali Pulendran, Emory University; Rafick-Pierre Sekaly, Emory University
• Language: English
• Date: 2021-08-01
• Publisher: AMER ASSOC ADVANCEMENT SCIENCE
• Publication Version: Final Published Version
• Copyright Statement: © 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S.Government Works.
• License: Creative Commons Attribution 4.0 International
• Final Published Version (URL): http://dx.doi.org/10.1126/sciimmunol.abf3733
• Title of Journal or Parent Work: SCIENCE IMMUNOLOGY
• Volume: 6
• Issue: 62
• Grant/Funding Information: This study is being supported by grants R01AI104870, R01AI132774, R01AI135803, R01AI145835, U19AI057229, U19AI062629, U19AI077439, U19AI089992, U19AI090023, U19AI118608, U19AI118610, U19AI125357, U19AI128910, U19AI128913, U54AI142766, U19AI089992, and U24AI52179 from the National Institute of Allergy and Infectious Diseases (NIAID), a part of the U.S. National Institutes of Health (NIH), and P51 OD011132, S10 OD026799 from NIH. The Precision Vaccines Program is supported, in part, by the Department of Pediatrics and Chief Scientific Officer of Boston Children’s Hospital.
• Keywords: Immunology; SELECTION; RNA-SEQ; WORKFLOW; Science & Technology; INFORMATION; Life Sciences & Biomedicine
• Research Categories: Health Sciences, Immunology

Abstract

The IMmunoPhenotyping Assessment in a COVID-19 Cohort (IMPACC) is a prospective longitudinal study designed to enroll 1000 hospitalized patients with COVID-19 (NCT04378777). IMPACC collects detailed clinical, laboratory and radiographic data along with longitudinal biologic sampling of blood and respiratory secretions for in depth testing. Clinical and lab data are integrated to identify immunologic, virologic, proteomic, metabolomic and genomic features of COVID-19-related susceptibility, severity and disease progression. The goals of IMPACC are to better understand the contributions of pathogen dynamics and host immune responses to the severity and course of COVID-19 and to generate hypotheses for identification of biomarkers and effective therapeutics, including optimal timing of such interventions. In this report we summarize the IMPACC study design and protocols including clinical criteria and recruitment, multi-site standardized sample collection and processing, virologic and immunologic assays, harmonization of assay protocols, high-level analyses and the data sharing plans.